Schulhoff & Co. Inc. Boosts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Schulhoff & Co. Inc. boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.6% in the third quarter, Holdings Channel reports. The institutional investor owned 2,600 shares of the company’s stock after purchasing an additional 270 shares during the period. Schulhoff & Co. Inc.’s holdings in Medpace were worth $868,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MEDP. Swiss National Bank raised its holdings in Medpace by 0.4% in the first quarter. Swiss National Bank now owns 48,400 shares of the company’s stock worth $19,561,000 after buying an additional 200 shares during the last quarter. ProShare Advisors LLC raised its holdings in Medpace by 3.1% in the 1st quarter. ProShare Advisors LLC now owns 3,337 shares of the company’s stock worth $1,349,000 after acquiring an additional 101 shares during the last quarter. Picton Mahoney Asset Management purchased a new position in Medpace in the 1st quarter worth approximately $2,926,000. Blair William & Co. IL boosted its stake in Medpace by 43.4% during the 1st quarter. Blair William & Co. IL now owns 24,851 shares of the company’s stock valued at $10,044,000 after purchasing an additional 7,521 shares during the last quarter. Finally, J.Safra Asset Management Corp boosted its stake in Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.3 %

Shares of NASDAQ MEDP opened at $361.94 on Thursday. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77. The firm has a market capitalization of $11.25 billion, a price-to-earnings ratio of 31.69, a price-to-earnings-growth ratio of 2.00 and a beta of 1.37. The firm has a 50 day moving average of $341.97 and a 200 day moving average of $376.72.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the previous year, the firm posted $2.22 EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MEDP. Robert W. Baird downgraded Medpace from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $413.00 to $349.00 in a report on Wednesday, October 23rd. TD Cowen lowered their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $380.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.